Nasal Spray Desmopressin – Noctiva- Reduces Nighttime Voiding in Patients With Nocturia Interview with:

Dr. Jed Kaminetsky - MD Clinical Assistant Professor Department of Urology NYU Langone Medical Center

Dr. Jed Kaminetsky

Dr. Jed Kaminetsky MD
Clinical Assistant Professor
Department of Urology
NYU Langone Medical Center What is the background for this study? What are the main findings?

Dr. Kaminetsky: Nocturia is a voiding disorder not well treated by available drugs for overactive bladder and benign prostatic hypertrophy. Desmopressin stimulates the kidneys to concentrate the urine which results in a greatly reduced volume of urine formation for a period of time. Serenity Pharmaceuticals has spent many years developing a low dose nasal spray version of desmopressin called Noctiva specifically for nocturia. The study reported now is a large, placebo controlled phase 3 trial to confirm the statistical efficacy and clinical benefit of this treatment for nocturia. What should clinicians and patients take away from your report?

Dr. Kaminetsky: There is a new treatment called Noctiva for nocturia which in clinical studies significantly decreases the number of nighttime voids and improves how patients feel concerning their nocturia. Noctiva is being considered by FDA for approval. What recommendations do you have for future research as a result of this study?

Dr. Kaminetsky: This study was a confirmatory Phase 3 trial for the Noctiva program which provides an important basis for possible approval of this drug by the FDA. Future studies may evaluate Noctiva in combination with other drugs used to treat conditions which can contribute to nocturia such as overactive bladder or benign prostatic hypertrophy. Is there anything else you would like to add?

Dr. Kaminetsky: Nocturia is a common and important medical condition which has particular impact on older patients in terms of sleep deprivation, less ability to function well during the daytime and greater risk of serious injury because of falling at night. It is not a lifestyle indication but an unmet medical need for which the medical community wants new and better treatments. Noctiva, if approved by the FDA, may be the first drug which we can offer to patients specifically for nocturia. Thank you for your contribution to the community.


2016 AUA abstract :

“A Randomized, Double-Blind, Placebo Controlled Study of 2 Doses of SER120 Nasal Spray in Patients with Nocturia” (conducted by Allergan development partner Serenity Pharmaceuticals LLC)

  • Moderated Poster – MP74; Room 24
  • Authors: Kaminetsky J, Wein A, Dmochowski R, Herschkowitz S, Cheng M, Abrams S, Fein S
  • May 9th 2016

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″] 






Last Updated on May 11, 2016 by Marie Benz MD FAAD